In support of this hypothesis, we showed that breast cancer patients, who express high levels of Nrf2 and its downstream targets NQO1, ABCC1 and ABCC3 at the time of initial diagnosis, had poorer survival following tamoxifen therapy. The gene discussed is NFE2L2; the disease is breast carcinoma.